TargetMol

sbp-7455

Product Code:
 
TAR-T8850
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8850-1mg1mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8850-5mg5mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8850-10mg10mg£233.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8850-25mg25mg£363.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8850-50mg50mg£548.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8850-100mg100mg£669.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
CAS:
1884222-74-5
Formula:
C16H17F3N4O2
Molecular Weight:
354.333
Pathway:
Autophagy
Purity:
0.9903
SMILES:
COc1ccc(Nc2ncc(c(NC3CC3)n2)C(F)(F)F)cc1OC
Target:
Autophagy

References

Ren H, Bakas NA, Vamos M, et al. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2020;63(23):14609-14625. doi:10.1021/acs.jmedchem.0c00873 Fenton S E, Zannikou M, Ilut L, et al.Targeting ULK1 decreases interferon-?-mediated resistance to immune checkpoint inhibitors.Molecular Cancer Research.2022